Page 92 - Read Online

Page 20 of 20 Ho et al. J Cancer Metastasis Treat 2019;5:70 I http://dx.doi.org/10.20517/2394-4722.2019.25

164. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein
ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther
2004;3:551-66.
165. Lamottke B, Kaiser M, Mieth M, Heider U, Gao Z, et al. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell
cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur J
Haematol 2012;88:406-15.
166. Stuhmer T, Iskandarov K, Gao Z, Bumm T, Grella E, et al. Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-
HSP990 against multiple myeloma cells. Anticancer Res 2012;32:453-62.
167. Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, et al. Posttranslational modification and conformational state of heat shock
protein 90 differentially affect binding of chemically diverse small molecule inhibitors. Oncotarget 2013;4:1065-74.
168. Usmani SZ, Bona RD, Chiosis G, Li Z. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition
of both HSP90A and HSP90B1. J Hematol Oncol 2010;3:40.
169. Stuhmer T, Zollinger A, Siegmund D, Chatterjee M, Grella E, et al. Signalling profile and antitumour activity of the novel Hsp90
inhibitor NVP-AUY922 in multiple myeloma. Leukemia 2008;22:1604-12.
170. Bailey CK, Budina-Kolomets A, Murphy ME, Nefedova Y. Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma. Cancer Biol
Ther 2015;16:1422-6.
171. Zhang L, Fok JJ, Mirabella F, Aronson LI, Fryer RA, et al. Hsp70 inhibition induces myeloma cell death via the intracellular
accumulation of immunoglobulin and the generation of proteotoxic stress. Cancer Lett 2013;339:49-59.
172. Davenport EL, Zeisig A, Aronson LI, Moore HE, Hockley S, et al. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced
apoptosis in myeloma. Leukemia 2010;24:1804-7.
173. Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, et al. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp)
90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines
and inhibits paracrine tumour growth. Br J Haematol 2007;136:414-23.
174. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific
apoptosis. Cancer Cell 2008;14:250-62.
175. Fok JHL, Hedayat S, Zhang L, Aronson LI, Mirabella F, et al. HSF1 is essential for myeloma cell survival and a promising therapeutic
target. Clin Cancer Res 2018;24:2395-407.
176. Onorati AV, Dyczynski M, Ojha R, Amaravadi RK. Targeting autophagy in cancer. Cancer 2018;124:3307-18.
177. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of
hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 2014;10:1380-90.
178. Montanari F, Lu M, Marcus S, Saran A, Malankar A, et al. A phase II trial of chloroquine in combination with bortezomib and
cyclophosphamide in patients with relapsed and refractory multiple myeloma. Blood 2014;124:5775.
179. Scott EC, Maziarz RT, Spurgeon SE, Medvedova E, Gajewski J, et al. Double autophagy stimulation using chemotherapy and mTOR
inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.
Haematologica 2017;102:e261-5.
180. Xie X, White EP, Mehnert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One
2013;8:e55096.
181. Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol
2016;104:300-9.
182. Yee AJ, Bensinger WI, Supko JG, Voorhees PM, Berdeja JG, et al. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or
refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol 2016;17:1569-78.
183. Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in
combination with Bortezomib and Dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res 2017;23:3307-15.
184. Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, et al. Tanespimycin with Bortezomib: activity in relapsed/refractory
patients with multiple myeloma. Br J Haematol 2010;150:428-37.
185. Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, et al. New molecular and biological mechanism of antitumor activities of KW-
2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res 2010;16:2792-802.
186. Yong K, Cavet J, Johnson P, Morgan G, Williams C, et al. Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell
malignancies. Br J Cancer 2016;114:7-13.
187. Cavenagh J, Oakervee H, Baetiong-Caguioa P, Davies F, Gharibo M, et al. A phase I/II study of KW-2478, an Hsp90 inhibitor, in
combination with bortezomib in patients with relapsed/refractory multiple myeloma. Br J Cancer 2017;117:1295-302.
188. Günther A, Baumann P, Burger R, Kellner C, Klapper W, et al. Activity of everolimus (RAD001) in relapsed and/or refractory
multiple myeloma: a phase I study. Haematologica 2015;100:541-7.
189. Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, et al. Outcomes in patients with relapsed or refractory multiple myeloma in
a phase I study of everolimus in combination with lenalidomide. Br J Haematol 2014;166:401-9.
190. Hitz F, Pabst T, Hess D, Kraus M, Besse L, et al. Nelfinavir and Lenalidomide/Dexamethasone in patients with lenalidomide-
refractory multiple myeloma. A Phase I/II Trial - SAKK 39/10. Blood 2017;130:1884.
191. Driessen C, Müller R, Novak U, Cantoni N, Betticher D, et al. Promising activity of nelfinavir-bortezomib-dexamethasone in
proteasome inhibitor-refractory multiple myeloma. Blood 2018;132:2097-100.